Navigation Links
USB OptiKinase Eliminates Base Bias in Labeling of Oligonucleotide 5'-Ends

Wild-type T4 Polynucleotide Kinase (PNK)(1,2,3) is commonly used for phosphorylation and labeling of 5'-ends of DNA and oligonucleotides. Labeling, in particular, can be accomplished by two approaches, the forward reaction and the exchange reaction (Fig. 1)(3). Historically, T4 PNK has played a crucial role in molecular biology and it continues to be important in applications such as labeling of probes for hybridization, sequencing or mapping of transcripts and in phosphorylation of DNA ends for cloning(3,4). Although T4 PNK continues to be widely used, the enzyme exhibits two limitations. First, T4 PNK exhibits base bias; the effectiveness of phosphorylation depends on the base at the 5'-end of the oligonucleotide target, with 5'-C exhibiting the lowest extent of phosphorylation(5). Second, T4 PNK can be challenging to use; precise enzyme titrations and careful optimization of reaction times are often required in order to achieve desired results(3,6). USB OptiKinase overcomes these limitations, greatly simplifying and improving phosphorylation and labeling reactions.

OptiKinase is a recombinant version of T4 PNK that has been genetically modified to accomplish uniform and consistent phosphorylation and labeling of 5'-ends of DNA and oligonucleotides. Base bias is dramatically reduced, which should greatly increase uniformity of labeling of diverse templates. The need for careful optimization of reaction conditions is also reduced, which should improve consistency of results between experiments. Finally, lower amounts of radioactive ATP can be used without sacrificing labeling efficiency, resulting in reduced reagent costs. Thus, USB OptiKinase offers substantial advantages over wild-type T4 PNK.


The following protocol corresponds to use of OptiKinase for labeling of oligonucleotides by the forward reaction. The protocol is similar to that for T4 PNK, with the exception that there is no need to use excess radiolabeled ATP.

2. Mix the contents well and centrifuge briefly. Incubate at 37C for 30 min.

3. Terminate the reaction by heating at 65C for 10 min.

Optional performance assay: The amount of radioactive phosphate incorporated into 5'-ends may be determined by separating 5'-end-labeled oligonucleotide from precursor ATP by binding to DE81 filter paper and washing the filter with a solution of 5% Sodium Phosphate dibasic.

* Either [γ-32P]ATP or [γ-33P]ATP (≥ 3000 Ci/mmol) may be used. Whether OptiKinase or T4 PNK is used, best results are obtained by using very fresh radiolabeled ATP. Even a few days (less than one half life) can dramatically decrease the specific activity of the final product.


OptiKinase offers a variety of advantages over T4 PNK. Primary among these is that OptiKinase overcomes base bias, allowing uniform labeling of oligonucleotides (Fig. 2). Additionally, OptiKinase shifts the reaction equilibrium toward phosphorylation, allowing efficient labeling with relatively lower amounts of radiolabel (Fig. 3). It performs well across a range of enzyme concentrations, eliminating the need for careful enzyme titrations (Fig. 4). OptiKinase works well for labeling of double-stranded oligonucleotides (Fig. 5). It can also be used for phosphorylation of oligonucleotides with non-labeled ATP and for labeling of variety of double-stranded DNA ends after restriction digestion and removal of the 5'-phosphate by phosphatase treatment (data not shown).


OptiKinase outperforms T4 PNK in a variety of 5'-labeling reactions, in terms of labeling uniformity, efficiency, and ease of use. For these reasons, OptiKinase is highly recommended for 5'-phosphorylation applications in general, and for 5'-labeling applications in particular.


1. GALBURT, E. A., PELLETIER, J., WILSON, G., AND STODDARD, B. L. (2002) Structure 10, 1249- 1260.

2. WANG, L. K., LIMA, C. D., AND SHUMAN, S. (2002) EMBO J. 21, 3873-3880.

3. RICHARDSON, C. C. (1981) The Enzymes , 3rd Edition, Ed. P. D. Boyer, (Academic Press, New York) 14, 299-314.

4. MAXAM, A. M. AND GILBERT, W. (1980) Methods in Enzymology 65, 499-560.

5. VAN HOUTEN, V., DENKERS, F., VAN DIJK, M., VAN DEN BREKEL, M. AND BRAKENHOFF, R. (1998) Anal. Biochemistry 265, 386-389.

6. LILLEHAUG, J. R. AND KLEPPE, K. (1975) Biochemistry 14, 1221-1225.



Page: All 1 2 3

Related biology technology :

1. New Microarray Labeling Kit for Preparing cDNA Probes
2. aRNA Synthesis and Labeling for Array Analysis
3. Amino Allyl Labeling for Array Analysis
4. Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit
5. Efficient Europium Labeling of Lymphokine-Activated Killer Cells Using the Gene Pulser II with RF Module, Rev C
6. Oligonucleotide Purity Analysis by Capillary Electrophoresis
7. Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21)
Post Your Comments:

(Date:10/13/2015)... , Oct. 13 2015 Research and ... "US & Europe Markets for Bone Morphogenetic Protein ... to their offering. --> ... that induce the formation of bone after a fracture. ... embryonic development in the formation of the skeleton. There ...
(Date:10/13/2015)... FLORHAM PARK, N.J. and SAN ... Corporation (BASF) and Mast Therapeutics, Inc. have agreed to ... 188.  Currently, excipient-grade poloxamer 188 NF, marketed by BASF ... polymer used in a variety of pharmaceutical and biological ... production. Poloxamer 188 is the starting material for Mast,s ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... distributor of automation systems, material handling solutions and components, is opening its latest ... near State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit ...
(Date:10/13/2015)... the United States , ... represents about 14% of all new cases of kidney cancer.   ... Canada and Europe .  PRCC represents ... --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces ... AB (publ) ("AstraZeneca") have completed enrolment in a global Phase II ...
Breaking Biology Technology:
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
(Date:9/30/2015)...  The global glucose monitoring device and diabetes management market ... new report on the industry from Kalorama Information. Sales in the ... followed by continuous glucose monitoring and sensor segment, according to ... these products in its latest report, The Global Glucose ... , ...
(Date:9/29/2015)...  iDAvatars is excited to be named one of the ... The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a demo ... "It is both an honor and a privilege ... to market the cognitive power of IBM Watson in our ...
Breaking Biology News(10 mins):